Continuous Glucose Monitoring (CGM) Devices Market Size, Share and Growth Outlook, 2026

Continuous Glucose Monitoring (CGM) Devices Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Continuous Glucose Monitoring (CGM) Devices Market size is forecast to increase from $18.18 Billion in 2026 to $56.78 Billion in 2034 at a CAGR of 15.3% between 2026 and 2034.

The Continuous Glucose Monitoring (CGM) Devices market report provides detailed analysis and outlook of Continuous Glucose Monitoring (CGM) Devices segments including By Component: (Sensors, Transmitters, Receivers, Applicators), By Connectivity: (Bluetooth, Near Field Communication, 4G), By Indication: (Type 1 Diabetes, Type 2 Diabetes), By End-User: (Hospitals, Home Care, Others) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Continuous Glucose Monitoring (CGM) Devices Industry Overview

Dual-Sensing Technology Expanding Diabetes Monitoring Capabilities

The Continuous Glucose Monitoring (CGM) Devices industry is advancing beyond traditional glucose measurement through the introduction of multi-analyte sensing platforms designed to improve diabetes management and complication prevention. One of the most significant innovations involves dual-sensing systems capable of measuring both glucose and ketone levels simultaneously every minute. These advanced sensors are specifically designed for individuals at elevated risk of diabetic ketoacidosis (DKA), including insulin-dependent Type 1 diabetes patients, insulin-treated Type 2 diabetes patients, and individuals using SGLT2 inhibitor therapies. By continuously monitoring ketone concentrations alongside glucose levels, the technology can alert users through a connected mobile application when ketone levels begin to rise, providing early warning of potential metabolic emergencies. This capability eliminates dependence on intermittent finger-stick blood testing or urine ketone strips while enabling more proactive disease management. Commercial rollout across select European markets is scheduled for late 2026, reflecting growing industry interest in comprehensive metabolic monitoring solutions.

Integrated Mobile Platforms Enhancing Insulin Therapy Management

Manufacturers are increasingly focusing on creating unified diabetes management ecosystems that combine sensor technology, insulin therapy insights, and digital health applications. A notable development is the integration of the low-profile, calibration-free Simplera™ CGM sensor into a comprehensive mobile platform designed for individuals managing diabetes through multiple daily insulin injections (MDI). The system operates as an integrated framework that synchronizes real-time glucose monitoring data with automated insulin dosing guidance within a single mobile application. By consolidating glucose tracking, therapy analytics, and treatment decision support into one platform, the technology simplifies diabetes management while reducing the complexity associated with multiple disconnected devices and applications. Such integrated solutions are helping improve user engagement, treatment adherence, and overall diabetes self-management outcomes.

Implantable Biosensor Technologies Driving Long-Term Monitoring Innovation

The CGM industry is also witnessing significant advancements in implantable biosensor technologies aimed at extending sensor lifespan and reducing device maintenance requirements. A newly developed continuous blood glucose monitoring (CBGM) platform is being designed as a fully implantable long-term monitoring solution capable of providing extended glucose tracking without the frequent sensor replacements required by conventional wearable systems. The technology is supported by a 240-day in-vivo ovine study that demonstrated sustained biosensor stability and consistent performance over prolonged implantation periods. In addition, newly issued patents covering the platform's implantable sensor geometry strengthen the intellectual property foundation supporting future commercialization efforts. The company plans to initiate U.S. clinical trials during the second half of 2026, representing an important step toward bringing long-duration implantable glucose monitoring systems to market. These innovations highlight the industry's continued focus on improving convenience, sensor longevity, and continuous metabolic monitoring for individuals living with diabetes.

Continuous Glucose Monitoring (CGM) Devices Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Continuous Glucose Monitoring (CGM) Devices market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Abbott Laboratories, Dexcom, Inc., Medtronic plc, Senseonics Holdings, Inc., Roche Diabetes Care (F. Hoffmann-La Roche Ltd.), Ascensia Diabetes Care (PHC Holdings), Novo Nordisk A/S, GlySens Incorporated, Biolinq Inc., A. Menarini Diagnostics S.r.l.. The Continuous Glucose Monitoring (CGM) Devices market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Continuous Glucose Monitoring (CGM) Devices industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Continuous Glucose Monitoring (CGM) Devices Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Continuous Glucose Monitoring (CGM) Devices companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Continuous Glucose Monitoring (CGM) Devices markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Continuous Glucose Monitoring (CGM) Devices Market Competitive Benchmarking and Company Analysis

Leading companies in Continuous Glucose Monitoring (CGM) Devices industry include- Abbott Laboratories, Dexcom, Inc., Medtronic plc, Senseonics Holdings, Inc., Roche Diabetes Care (F. Hoffmann-La Roche Ltd.), Ascensia Diabetes Care (PHC Holdings), Novo Nordisk A/S, GlySens Incorporated, Biolinq Inc., A. Menarini Diagnostics S.r.l.. The Continuous Glucose Monitoring (CGM) Devices market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Continuous Glucose Monitoring (CGM) Devices Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Continuous Glucose Monitoring (CGM) Devices market remains one of the strongest-performing segments in the country.
The US Continuous Glucose Monitoring (CGM) Devices Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Continuous Glucose Monitoring (CGM) Devices market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Continuous Glucose Monitoring (CGM) Devices industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Continuous Glucose Monitoring (CGM) Devices markets

Canada's strong Continuous Glucose Monitoring (CGM) Devices sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Continuous Glucose Monitoring (CGM) Devices market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Continuous Glucose Monitoring (CGM) Devices Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Continuous Glucose Monitoring (CGM) Devices market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Continuous Glucose Monitoring (CGM) Devices population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Continuous Glucose Monitoring (CGM) Devices industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Continuous Glucose Monitoring (CGM) Devices market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Continuous Glucose Monitoring (CGM) Devices sales through 2034

France Continuous Glucose Monitoring (CGM) Devices companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Continuous Glucose Monitoring (CGM) Devices Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Continuous Glucose Monitoring (CGM) Devices distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Continuous Glucose Monitoring (CGM) Devices Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Continuous Glucose Monitoring (CGM) Devices market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Continuous Glucose Monitoring (CGM) Devices industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Continuous Glucose Monitoring (CGM) Devices industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Continuous Glucose Monitoring (CGM) Devices Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Continuous Glucose Monitoring (CGM) Devices market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Continuous Glucose Monitoring (CGM) Devices market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Continuous Glucose Monitoring (CGM) Devices Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Continuous Glucose Monitoring (CGM) Devices Market Segmentation

By Component:
Sensors
Transmitters
Receivers
Applicators
By Connectivity:
Bluetooth
Near Field Communication
4G
By Indication:
Type 1 Diabetes
Type 2 Diabetes
By End-User:
Hospitals
Home Care
Others

Top Companies in Continuous Glucose Monitoring (CGM) Devices Industry

Abbott Laboratories
Dexcom, Inc.
Medtronic plc
Senseonics Holdings, Inc.
Roche Diabetes Care (F. Hoffmann-La Roche Ltd.)
Ascensia Diabetes Care (PHC Holdings)
Novo Nordisk A/S
GlySens Incorporated
Biolinq Inc.
A. Menarini Diagnostics S.r.l.

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025